<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533441</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE K study</org_study_id>
    <nct_id>NCT01533441</nct_id>
  </id_info>
  <brief_title>Vitamin K2 Intervention in Patients With Vitamin K Antagonists</brief_title>
  <acronym>SAFEK</acronym>
  <official_title>Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the SAFE K study is to demonstrate that in patients treated with the
      antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally
      produced by the ferments used in fermented dairy products, does not upset the balance of
      anticoagulant treatment.Fifty-two patients will be chosen to receive either verum or placebo
      for four months after a 4-month run-in period.In addition, the study evaluates if regular
      consumption of vitamin K2 reduce the need of changing the dose of anticoagulation treatment
      and improve the markers of bone mineralisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomisation of the study subjects will be done by two randomisation lists depending on
      whether the dose of VKA is high or low. Randomisation will be balanced and stratified
      depending on the average dose of VKA before the inclusion in order that each arm would have
      the same number of patients receiving a dose lower than the used anticoagulant treatments.

      The level of vitamin K intake will be determined during the study visits using dietary
      questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INR</measure>
    <time_frame>change from baseline at two months</time_frame>
    <description>Prothrombin time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>INR</measure>
    <time_frame>change from baseline at four months</time_frame>
    <description>prothrombin time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>c/uc osteocalcin ratio</measure>
    <time_frame>change from baseline at two months</time_frame>
    <description>immunoassay method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVII from plasma</measure>
    <time_frame>change from baseline at two months</time_frame>
    <description>chronometric method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FII</measure>
    <time_frame>change from baseline at two months</time_frame>
    <description>chronometric method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma vitamin K levels</measure>
    <time_frame>change from base-line at two months</time_frame>
    <description>HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c/uc osteocalcin ratio</measure>
    <time_frame>change from baseline at four months</time_frame>
    <description>immunoassay method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVII</measure>
    <time_frame>change from baseline at four months</time_frame>
    <description>chronometric method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FII</measure>
    <time_frame>change from baseline at four months</time_frame>
    <description>chronometric method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma vitamin K level</measure>
    <time_frame>change from baseline at four months</time_frame>
    <description>HPLC</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>placebo low VKA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo high VKA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K2 Low VKA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K2 high VKA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2</intervention_name>
    <description>4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention</description>
    <arm_group_label>placebo low VKA</arm_group_label>
    <arm_group_label>Placebo high VKA</arm_group_label>
    <arm_group_label>Vitamin K2 Low VKA</arm_group_label>
    <arm_group_label>Vitamin K2 high VKA</arm_group_label>
    <other_name>phylloquinone,</other_name>
    <other_name>menaquinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treated with anticoagulants

          -  INR range between 2-3

          -  TTR (time in therapeutic range)equal or higher 56% during the 4 months before the
             inclusion

        Exclusion Criteria:

          -  consumption of significant amounts of products conatining vitamin K

          -  regular consumption of dietary supplements susceptible to contain vitamin K

          -  milk intolerant or refusing a daily consumption of dairy product

          -  previous insufficient earlier therapeutic VKA follow-up

          -  cardiac, renal or severe respiratory insufficiency, diseases interfering fat
             absorption, significant abnormalities in safety parameters, clinically significant
             thrombotic or hemorrhagic event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsti Tiihonen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Danisco Sweeteners Oy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludovic Drouet, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>IVS/CREATIF, Hopital Lariboisiere</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Bal dit Sollier</last_name>
    <role>Study Chair</role>
    <affiliation>IVS/CREATIF, Hopital Lariboisiere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unite de Recherches Therapeutiques, Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulant therapy</keyword>
  <keyword>INR</keyword>
  <keyword>vitamin K2</keyword>
  <keyword>vitamin K antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

